



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Siegel

SERIAL NO.:

10/632,212

**GROUP NO.:** 

3736

FILING DATE:

July 31, 2003

**EXAMINER:** 

Not yet assigned

TITLE:

Measuring Circulating Blood Volume Through Retinal Vasculometry

## CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 27th day of April, 2004.

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

#### Submitted herewith are:

- 1. Transmittal Form (1 pg.);
- 2. Information Disclosure Statement (2 pgs.);
- 3. PTO Form 1449 (2 pgs.);
- 4. references (B1 and C1-C14); and
- 5. a return-receipt postcard.

3058101



/	\ ':>	IF	E	
188	APR	2 9	2004	
₽\$	<b>8</b> .		کیہ	\$P

# TRANSMITTAL FORM

Application Serial Number	10/632,212
Filing Date	July 31, 2003
First Named Inventor	Siegel
Group Art Unit	3736
Examiner Name	Not Yet Assigned
Attorney Docket No.	MIT-146 (5473/167)

	1 Oldvi								
_			Attorney Do	cket No.	MIT-146 (	5473/167)			
ENCLOSURES (check all that apply)									
Fee Transmittal Form		F	Copy of Notice Parts of Applica FORM PTO-15			Appeal Communication to Board of Appeals and Interferences			
	☐ Check Attached☐ Copy of Fee Transmittal Form	`	Formal Drawing	•		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
	Amendment/Response		Petition Routing and Accompany	g Slip (PTO/SB/69	9)   -	Status Letter			
	☐ After Final ☐ Affidavits/declaration(s)	_ 7	Γο Convert to a	•		Return Receipt Postcard			
	Letter to Official Draftsperson		Application			Certificate of First Class Mailing under 37 C.F.R. 1.8			
	including Drawings [Total Sheets]	Power of Attorney (Revocation of Prior Powers)				Additional Enclosure(s) (please identify below)			
☐ Time Ur	Petition for Extension of oder 37 CFR 1.136(a)	☐ Terminal Disclaimer			· ,				
⊠	Information Disclosure Statement		Executed Declaration and Power of Attorney for Utility or Design Patent Application		of				
$\boxtimes$	Form PTO-1449 Copies of IDS Citations B1 and C1-C14		Small Entity Sta						
	Certified Copy of Priority Document(s)	Request for Refund							
	Response to Notice to File Missing Parts of Application Executed Declaration and Power of Attorney For Utility or Design Application	After Allowand to Group		e Communication					
CORRESPONDENCE ADDRESS				SIGNATURE	BLOCK				
Direct all correspondence to:  Patent Administrator Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110 Tel. No.: (617) 248-7000 Fax No.: (617) 248-7100			ibeault, LLP . 7000	Date: April 27, 2 Reg. No. 35,722 Tel. No.: (617) 2 Fax No.: (617) 2	: 248-7738	Respectfully submitted,  Thomas A. Turano Attorney for Applicants Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Roston, MA, 02110			

3058084



# INPARE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Siegel

SERIAL NO.:

10/632,212

**GROUP NO.:** 

3736

FILING DATE:

July 31, 2003

**EXAMINER:** 

Not Yet Assigned

TITLE:

Measuring Circulating Blood Volume Through Retinal Vasculometry

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

## **REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1)	within three (3) months of the <b>filing date</b> of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the <b>date of entry of the national stage</b> as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the <b>first Office action</b> on the merits, or before the mailing of a <b>first Office action</b> after the filing of a request for continued examination under 37 C.F.R. 1.114; or
(2)	after the period defined in (1) but before the mailing date of a <b>final action</b> or a <b>notice of allowance</b> under 37 C.F.R. 1.311, and
	the requisite Statement is below, OR
	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or
(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND

Information Disclosure Statement Serial No. 10/632,212 Page 2 of 2

the requisite Statement is below, AND
the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

#### **STATEMENT**

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Date: April 27, 2004 Reg. No. 35,722

Tel. No.: (617) 248-7738 Fax No.: (617) 248-7100

Thomas A. Turano
Attorney for Applicant

Testa, Hurwitz, & Thibeault, LLP

-67

High Street Tower 125 High Street

Boston, Massachusetts 02110



FORM PTO - 1449				ATTORNEY DOCKET NO.: MIT-146							
INFORMATION DISCLOSURE STATEMENT					APPLICANT(S): Siegel						
					SERIAL	NO.: 10/6	532,212				
					FILING I	DATE: 7/	31/03	GRO	UP:	3736	
			U.	S. PATENT	DOCUM	ENTS					
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME			CLASS	SUB CLASS	1	FILING DATE IF APPROPRIATE	
	Al	6,701,169	03/02/04	Denningh	off						
EXAMIN	ER				DATE C	ONSIDER	ED			•	
			FORE	IGN PATE	NT DOC	UMENTS	3	·			
EXAM INIT.		DOCUMENT NUMBER.	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRA ONLY	ACT	ENGLISH LANG. (Y/N)	
	Bl	WO 00/65986	11/09/00	PCT			04/28/00				
EXAMIN	ER				DATE CONSIDERED						
			OTHER A	RT, JOUR	NAL ART	CICLES, 1	ETC.				
EXAM. INIT.	ОТН	IER DOCUMENT	rs: (Includin	g Author, Tit	le, Date, Re	elevant Pag	ges, Place of	Publication	on)		
	CI		Denninghoff & Smith, "An Optical Model of the Blood in Large Retinal Vessels" J. Biomed Opt., 5(4), 371-4 (October 2000)								
	C2	Smith et al., "Retinal vessel oximetry: Toward absolute calibration" <a href="Proceedings SPIE Vol. 3908">Proceedings SPIE Vol. 3908</a> , <a href="Ophthalmic Technologies X, Pascal O. Rol; Karen M. Joos; Fabrice Manns; Eds">Pascal O. Rol; Karen M. Joos; Fabrice Manns; Eds</a> . 217-226 (June 2000)									
	C3	Lompado et al., "Multi-spectral confocal scanning laser opthalmoscope for retinal vessel oximetry" Spectral imaging: Instrumentation, applications, and analysis, G. H. Bearman, D. Cabib, R. M. Levenson, eds., Proceedings of SPIE Vol. 3920, (2000)									
	C4	C4 Lompado et al., "In-plane scatterometry of a small caliber blood column," Optical Diagnostics of Biological Fluids V, A. V. Priezzhev, T. Asakura, eds., Proceedings Of SPIE Vol. 3923, (2000)									
	C5	Drewes et al., "An Instrument for the Measurement of Retinal Vessel Oxygen Saturation" Optical  Diagnostics of Biological Fluids IV, Alexander V. Priezzhev, M. V. Lomonosov, Toshimitsu Asakura, eds.,  Proceedings Of SPIE Vol. 3591, 114-120 (1999)									
·	C6	Smith, Matthew H., "Optimum wavelength combinations for retinal vessel oximetry," <u>Applied Optics</u> , <u>38(1)</u> , 258-267 (January 1999)									
	C7 Smith et al., "Effect of multiple light paths on retinal vessel oximetry" Applied Optics, 39 (7), 1183-1193 (2000)										
EXAMIN	ER				DATE C	ONSIDER	ED				

FORM PTO - 1449			ATTORNEY DOCKET NO.: MIT-146				
INFORM	1ATIO	N DISCLOSURE STATEMENT	APPLICANT(S): Siegel				
			SERIAL NO.: 10/632,212				
			FILING DATE: 7/31/03 GROUP: 3736				
		FOREIGN PATE	NT DOCUMENTS				
EXAM. INIT.	ОТН	ER DOCUMENTS: (Including Author, Ti	tle, Date, Relevant Pages, Place of Publication)				
	C8	Denninghoff, Smith & Hillman; "Retinal Imaging Techniques in Diabetes" <u>Diabetes Technol Ther.</u> , 2 (1), 111-3 (Spring 2000)					
	C9	Denninghoff et al., "Retinal Venous Oxygen Saturation Correlates with Blood Volume," <u>Academic Emergency Medicine</u> , <u>5(6)</u> , 577-582 (June 1998)					
	C10	Smith et al., "Oxygen Saturation Measurements of Blood in Retinal Vessels During Blood Loss," <u>Journal of Biomedical Optics</u> , 3(3), 296-303 (July 1998)					
	C11	Denninghoff et al., "Retinal Large Vessel Oxygen Saturations Correlate with Early Blood Loss and Hypoxia in Anesthetized Swine," The Journal of Trauma: Injury, Infection and Critical Care, 43(1), 29-34(July 1997)					
	C12	Denninghoff, Kurt, "An Eye Oximeter for Combat Casualty Care," University of Alabama at Birmingham (December 1999)					
	C13	Heaton et al., "Handheld Four-Wavelength Retinal Vessel Oximeter", <u>Progress in Biomedical Optics and Imaging</u> , 1(2), 227-233 (January 2000)					
_	C14	Denninghoff et al., "Retinal Venous Oxygen Saturation and Cardiac Output During Controlled Hemorrhage and Resuscitation." <u>Journal of Applied Physiology. 94 (3)</u> 891-896 (March 2003)					
EXAMIN	ER		DATE CONSIDERED				

3052945